Verdiva Bio is a technology company.
Verdiva Bio has raised $410.0M across 1 funding round.
Verdiva Bio has raised $410.0M in total across 1 funding round.
Verdiva Bio has raised $410.0M in total across 1 funding round.
Verdiva Bio's investors include Forbion, General Atlantic.
Verdiva Bio is a clinical-stage biopharmaceutical company developing next-generation oral and injectable therapies for obesity, cardiometabolic disorders, and related complications, with a focus on patient-friendly options like once-weekly dosing.[1][2][5] Its lead candidate, VRB-101, is an oral GLP-1 receptor agonist (GLP-1RA) that showed promising Phase 1 efficacy and once-weekly dosing viability; the portfolio also includes oral and subcutaneous amylin agonists for enhanced weight loss and tolerability, licensed from Sciwind Biosciences for global rights outside Greater China and South Korea.[1][3][4] Launched in January 2025 with a record $411 million oversubscribed Series A led by Forbion and General Atlantic—participating investors include RA Capital, OrbiMed, Lilly Asia Ventures, and LYFE Capital—Verdiva serves patients seeking scalable, accessible treatments amid booming demand for obesity drugs, demonstrating strong early momentum through Phase 1 data and June 2025 preclinical updates on combinations.[1][3][4][7]
Verdiva Bio emerged in early 2025 from a team of biotech veterans, co-founded by Khurem Farooq—former CEO of Aiolos Bio (sold to GSK for $1 billion in 2024) and Gyroscope Therapeutics—as CEO, with Mark Pruzanski (ex-CEO of Versanis Bio and Intercept Pharmaceuticals founder) as Chairman.[1][3][4] The leadership includes ex-Aiolos executives like Chief Scientific Officer Jane Hughes, Chief Business Officer Tapan Maniar, and Chief Technology Officer Ashley Taylor, plus talent from Boehringer Ingelheim, bringing proven drug development expertise in gut-brain biology.[3][4] The idea crystallized around licensing Sciwind's portfolio in 2024, capitalizing on Chinese innovation in obesity meds; Verdiva launched publicly on January 9, 2025 (noted variably as 2024 in some early reports), instantly securing massive funding and advancing VRB-101 from Phase 1 in Australia to Phase 2 readiness.[1][3][4][7]
Verdiva rides the explosive obesity drug wave, fueled by GLP-1 successes like Novo Nordisk's Wegovy and Eli Lilly's Zepbound, where the market is projected to hit hundreds of billions; timing is ideal post-2024 Chinese biotech deals, as Western firms license validated assets to accelerate development.[3][4] Market forces favor it: surging demand for orals (avoiding injection barriers), combination therapies for sustained weight loss, and scalability amid supply shortages; Verdiva exemplifies the trend of U.S./UK biotechs building around China-sourced molecules (e.g., like Kailera, Aiolos), democratizing innovation and countering Big Pharma dominance.[1][3][4] It influences the ecosystem by validating oral delivery for cardiometabolics, potentially lowering costs and expanding access for millions with obesity complications.[2][5]
Verdiva is primed for Phase 2 readouts on VRB-101 and amylin combos in 2026, with potential partnerships or further funding to fuel global trials and commercialization. Rising oral GLP-1 demand, combo efficacy data (e.g., June 2025 ADA poster), and team track record position it to capture share in a market shifting toward convenient, differentiated therapies.[7][9] Influence could grow via Big Pharma buyouts, mirroring Aiolos, as it shapes gut-brain standards—watch for monotherapy breakthroughs tying back to its launch promise of transforming cardiometabolic care.[1][4]
Verdiva Bio has raised $410.0M across 1 funding round. Most recently, it raised $410.0M Series A in January 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2025 | $410.0M Series A | Forbion, General Atlantic |